The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

One analyst tracking the biotech upgraded her recommendation on its shares. She now believes that they rate a buy, rather than a hold. 10 stocks we like better than Recursion Pharmaceuticals › An ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

Hiking provides immense cardiovascular and musculoskeletal benefits, but being in nature while participating in the activity might be the greatest advantage of all. When hiking on challenging terrain, ...

Thomas Anderson – otherwise known as Neo – is walking up a flight of stairs when he sees a black cat shake itself and walk past a doorway. Then the moment seems to replay before his eyes. Just a touch ...

Jason Chun is a CNET writer covering a range of topics in tech, home, wellness, finance and streaming services. He is passionate about language and technology, and has been an avid writer/reader of ...

Artificial intelligence has become almost impossible to avoid, and for many, it's slowly replacing Google and other search engines. But while ChatGPT and its competitors can be useful, it's important ...

Nearly a third of US teenagers say they use AI chatbots daily, a new study finds, shedding light on how young people are embracing a technology that’s raised critical safety concerns around mental ...